ID   Namalwa
AC   CVCL_0067
SY   NAMALWA; Namalwa IV; Namalva; NAMALVA; NWA; NK62a
DR   BTO; BTO:0003289
DR   CLO; CLO_0007939
DR   EFO; EFO_0002246
DR   CLDB; cl3633
DR   CLDB; cl3634
DR   CLDB; cl3635
DR   CLDB; cl3636
DR   CLDB; cl3637
DR   AddexBio; C0003013/4670
DR   ArrayExpress; E-MTAB-38
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   ATCC; CRL-1432
DR   BCRC; 60553
DR   BCRJ; 0181
DR   BioSample; SAMN01821584
DR   BioSample; SAMN01821651
DR   BioSample; SAMN03473179
DR   BioSample; SAMN10988039
DR   Cell_Model_Passport; SIDM00641
DR   CGH-DB; 9201-4
DR   ChEMBL-Cells; CHEMBL3307288
DR   ChEMBL-Targets; CHEMBL614049
DR   CLS; 300439
DR   Cosmic; 929814
DR   Cosmic; 931107
DR   Cosmic; 998717
DR   Cosmic; 1037702
DR   Cosmic; 1086329
DR   Cosmic; 1818345
DR   Cosmic; 2701743
DR   Cosmic; 2814540
DR   Cosmic; 2823076
DR   Cosmic-CLP; 908159
DR   DepMap; ACH-000944
DR   DSMZCellDive; ACC-24
DR   ECACC; 87060801
DR   EGA; EGAS00001000610
DR   EGA; EGAS00001000978
DR   GDSC; 908159
DR   GEO; GSM99385
DR   GEO; GSM119534
DR   GEO; GSM499728
DR   GEO; GSM499734
DR   GEO; GSM862851
DR   GEO; GSM862852
DR   GEO; GSM862853
DR   GEO; GSM862854
DR   GEO; GSM862855
DR   GEO; GSM862856
DR   GEO; GSM862857
DR   GEO; GSM862858
DR   GEO; GSM888424
DR   GEO; GSM907523
DR   GEO; GSM1374695
DR   GEO; GSM1670143
DR   IARC_TP53; 175
DR   JCRB; IFO50040
DR   LiGeA; CCLE_320
DR   Lonza; 73
DR   NCBI_Iran; C126
DR   PharmacoDB; NAMALWA_981_2019
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_0067
DR   RCB; RCB0445
DR   TOKU-E; 2556
DR   Wikidata; Q54907447
RX   DOI=10.11418/jtca1981.15.4_211;
RX   PubMed=170370;
RX   PubMed=216485;
RX   PubMed=464569;
RX   PubMed=1325212;
RX   PubMed=1339415;
RX   PubMed=1915267;
RX   PubMed=2052620;
RX   PubMed=2415623;
RX   PubMed=2580922;
RX   PubMed=2830981;
RX   PubMed=2985879;
RX   PubMed=2998993;
RX   PubMed=3026973;
RX   PubMed=3080238;
RX   PubMed=3159941;
RX   PubMed=3874327;
RX   PubMed=4122458;
RX   PubMed=4347031;
RX   PubMed=4364259;
RX   PubMed=6231253;
RX   PubMed=6286763;
RX   PubMed=6811418;
RX   PubMed=7316467;
RX   PubMed=7849311;
RX   PubMed=8344493;
RX   PubMed=8402660;
RX   PubMed=8515068;
RX   PubMed=8558920;
RX   PubMed=9192833;
RX   PubMed=9473234;
RX   PubMed=9973220;
RX   PubMed=10739008;
RX   PubMed=11226526;
RX   PubMed=12145705;
RX   PubMed=16960149;
RX   PubMed=18357372;
RX   PubMed=20215515;
RX   PubMed=20454443;
RX   PubMed=21269460;
RX   PubMed=22460905;
RX   PubMed=22885699;
RX   PubMed=24590883;
RX   PubMed=25355872;
RX   PubMed=25485619;
RX   PubMed=25960936;
RX   PubMed=27397505;
RX   PubMed=28196595;
RX   PubMed=29892436;
RX   PubMed=30285677;
RX   PubMed=30629668;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=35839778;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Part of: MD Anderson Cell Lines Project.
CC   Population: African; Kenyan.
CC   Characteristics: Contains 2 integrated copies of EBV genome on chromosome 1.
CC   Characteristics: Infected by squirrel monkey retrovirus (SMRV) (PubMed=1339415; PubMed=20454443).
CC   Doubling time: 18 hours (PubMed=8402660); ~20-30 hours (DSMZ).
CC   HLA typing: A*66:02,29:02; B*57:03,58:01; C*15:05,07:01; DQA1*03:02,01:02; DQB1*06:02,02:01; DRB1*07:01,15:03 (PubMed=25960936).
CC   HLA typing: A*03:01:01,20:02:01; B*07:02:01,01:01:01; C*07:01:02,07:02:01; DPB1*01:01:01,02:01:02; DQA1*01:02:01,03:03:01; DQB1*03:02:01.06:02:01; DRB1*04:05:01,15:03:01 (CLS).
CC   Microsatellite instability: Instable (MSI-low) (PubMed=10739008; PubMed=11226526; Sanger).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Unspecified (PubMed=2052620; PubMed=8344493; PubMed=8402660; Cosmic-CLP; DepMap).
CC   Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
CC   Omics: Array-based CGH.
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: Deep RNAseq analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Deep proteome analysis.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis.
CC   Omics: Virome analysis using RNAseq.
CC   Genome ancestry: African=94.65%; Native American=0%; East Asian, North=1.43%; East Asian, South=0%; South Asian=0%; European, North=0%; European, South=3.91% (PubMed=30894373).
CC   Caution: Indicated to have an additional TP53 p.Arg248Trp (c.742C>T) mutation according to PubMed=2052620, but not confirmed by other references or by CCLE and Cosmic-CLP.
CC   Misspelling: NAMALLA; In Cosmic 998717.
CC   Discontinued: RCB; RCB0445; true.
ST   Source(s): AddexBio; ATCC; CLS; Cosmic-CLP; DSMZ; ECACC; JCRB; PubMed=25877200
ST   Amelogenin: X
ST   CSF1PO: 10,11
ST   D13S317: 11,12
ST   D16S539: 9
ST   D18S51: 15
ST   D19S433: 14,18
ST   D21S11: 27,28
ST   D2S1338: 17,21
ST   D3S1358: 16
ST   D5S818: 12,13
ST   D7S820: 11
ST   D8S1179: 13,15
ST   FGA: 22
ST   Penta D: 8,13
ST   Penta E: 5,15
ST   TH01: 7,9.3
ST   TPOX: 6,11
ST   vWA: 14
DI   NCIt; C27694; EBV-related Burkitt lymphoma
DI   ORDO; Orphanet_543; Burkitt lymphoma
OX   NCBI_TaxID=9606; ! Homo sapiens
SX   Female
AG   Children
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 22-09-22; Version: 42
RX   DOI=10.11418/jtca1981.15.4_211;
RA   Matsuo Y., Okochi A., Ariyasu T., Iimura E., Ohno T.;
RT   "Identification of cell lines with variable numbers of tandem repeat
RT   (VNTR) amplified by polymerase chain reaction.";
RL   Tissue Cult. Res. Commun. 15:211-219(1996).
RX   PubMed=170370; DOI=10.1099/0022-1317-28-2-207;
RA   Adams A., Strander H., Cantell K.;
RT   "Sensitivity of the Epstein-Barr virus transformed human lymphoid cell
RT   lines to interferon.";
RL   J. Gen. Virol. 28:207-217(1975).
RX   PubMed=216485;
RA   Higgins N.P., Strauss B.S.;
RT   "Differences in the ability of human lymphoblastoid lines to exclude
RT   bromodeoxyuridine and in their sensitivity to methyl methanesulfonate
RT   and to incorporated [3H]thymidine.";
RL   Cancer Res. 39:312-320(1979).
RX   PubMed=464569; DOI=10.1128/AAC.15.3.420;
RA   Klein F., Ricketts R.T., Jones W.I., DeArmon I.A., Temple M.J.,
RA   Zoon K.C., Bridgen P.J.;
RT   "Large-scale production and concentration of human lymphoid
RT   interferon.";
RL   Antimicrob. Agents Chemother. 15:420-427(1979).
RX   PubMed=1325212; DOI=10.1182/blood.V80.5.1289.1289;
RA   Benjamin D., Knobloch T.J., Dayton M.A.;
RT   "Human B-cell interleukin-10: B-cell lines derived from patients with
RT   acquired immunodeficiency syndrome and Burkitt's lymphoma
RT   constitutively secrete large quantities of interleukin-10.";
RL   Blood 80:1289-1298(1992).
RX   PubMed=1339415; DOI=10.1002/ijc.2910520320;
RA   Middleton P.G., Miller S., Ross J.A., Steel C.M., Guy K.;
RT   "Insertion of SMRV-H viral DNA at the c-myc gene locus of a BL cell
RT   line and presence in established cell lines.";
RL   Int. J. Cancer 52:451-454(1992).
RX   PubMed=1915267; DOI=10.1002/j.1460-2075.1991.tb07837.x;
RA   Farrell P.J., Allan G.J., Shanahan F., Vousden K.H., Crook T.;
RT   "p53 is frequently mutated in Burkitt's lymphoma cell lines.";
RL   EMBO J. 10:2879-2887(1991).
RX   PubMed=2052620; DOI=10.1073/pnas.88.12.5413;
RA   Gaidano G., Ballerini P., Gong J.Z., Inghirami G., Neri A.,
RA   Newcomb E.W., Magrath I.T., Knowles D.M., Dalla-Favera R.;
RT   "p53 mutations in human lymphoid malignancies: association with
RT   Burkitt lymphoma and chronic lymphocytic leukemia.";
RL   Proc. Natl. Acad. Sci. U.S.A. 88:5413-5417(1991).
RX   PubMed=2415623;
RA   Goldmacher V.S., Lambert J.M., Young A.Y., Anderson J., Tinnel N.L.,
RA   Kornacki M., Ritz J., Blattler W.A.;
RT   "Expression of the common acute lymphoblastic leukemia antigen (CALLA)
RT   on the surface of individual cells of human lymphoblastoid lines.";
RL   J. Immunol. 136:320-325(1986).
RX   PubMed=2580922; DOI=10.1089/jir.1985.5.65;
RA   Feinstein S., Traub A., Lazar A., Mizrahi A., Teitz Y.;
RT   "Studies on cell binding and internalization of human lymphoblastoid
RT   (Namalva) interferon.";
RL   J. Interferon Res. 5:65-76(1985).
RX   PubMed=2830981; DOI=10.1016/0092-8674(88)90530-2;
RA   Lawrence J.B., Villnave C.A., Singer R.H.;
RT   "Sensitive, high-resolution chromatin and chromosome mapping in situ:
RT   presence and orientation of two closely integrated copies of EBV in a
RT   lymphoma line.";
RL   Cell 52:51-61(1988).
RX   PubMed=2985879; DOI=10.1016/0145-2126(85)90084-0;
RA   Drexler H.G., Gaedicke G., Minowada J.;
RT   "Isoenzyme studies in human leukemia-lymphoma cell lines -- 1.
RT   carboxylic esterase.";
RL   Leuk. Res. 9:209-229(1985).
RX   PubMed=2998993;
RA   Steel C.M., Morten J.E.N., Foster E.;
RT   "The cytogenetics of human B lymphoid malignancy: studies in Burkitt's
RT   lymphoma and Epstein-Barr virus-transformed lymphoblastoid cell
RT   lines.";
RL   IARC Sci. Publ. 60:265-292(1985).
RX   PubMed=3026973; DOI=10.1002/ijc.2910390215;
RA   Ehlin-Henriksson B., Manneborg-Sandlund A., Klein G.;
RT   "Expression of B-cell-specific markers in different Burkitt lymphoma
RT   subgroups.";
RL   Int. J. Cancer 39:211-218(1987).
RX   PubMed=3080238;
RA   Sieverts H., Alabaster O., Goldschmidts W., Magrath I.T.;
RT   "Expression of surface antigens during the cell cycle in different
RT   growth phases of American and African Burkitt's lymphoma cell lines.";
RL   Cancer Res. 46:1182-1188(1986).
RX   PubMed=3159941; DOI=10.1016/0145-2126(85)90134-1;
RA   Drexler H.G., Gaedicke G., Minowada J.;
RT   "Isoenzyme studies in human leukemia-lymphoma cell lines -- III.
RT   Beta-hexosaminidase (E.C.";
RL   Leuk. Res. 9:549-559(1985).
RX   PubMed=3874327; DOI=10.1016/0145-2126(85)90133-x;
RA   Drexler H.G., Gaedicke G., Minowada J.;
RT   "Isoenzyme studies in human leukemia-lymphoma cells lines -- II. Acid
RT   phosphatase.";
RL   Leuk. Res. 9:537-548(1985).
RX   PubMed=4122458; DOI=10.1002/ijc.2910100108;
RA   Klein G., Dombos L., Gothoskar B.;
RT   "Sensitivity of Epstein-Barr virus (EBV) producer and non-producer
RT   human lymphoblastoid cell lines to superinfection with EB-virus.";
RL   Int. J. Cancer 10:44-57(1972).
RX   PubMed=4347031; DOI=10.1093/jnci/48.1.87;
RA   Hewetson J.F., Gothoskar B., Klein G.;
RT   "Radioiodine-labeled antibody test for the detection of membrane
RT   antigens associated with Epstein-Barr virus.";
RL   J. Natl. Cancer Inst. 48:87-94(1972).
RX   PubMed=4364259; DOI=10.1002/ijc.2910110210;
RA   Klein G., Dombos L.;
RT   "Relationship between the sensitivity of EBV-carrying lymphoblastoid
RT   lines to superinfection and the inducibility of the resident viral
RT   genome.";
RL   Int. J. Cancer 11:327-337(1973).
RX   PubMed=6231253; DOI=10.1002/ijc.2910330407;
RA   Ehlin-Henriksson B., Klein G.;
RT   "Distinction between Burkitt lymphoma subgroups by monoclonal
RT   antibodies: relationships between antigen expression and type of
RT   chromosomal translocation.";
RL   Int. J. Cancer 33:459-463(1984).
RX   PubMed=6286763;
RA   Benjamin D., Magrath I.T., Maguire R.T., Janus C., Todd H.D.,
RA   Parsons R.G.;
RT   "Immunoglobulin secretion by cell lines derived from African and
RT   American undifferentiated lymphomas of Burkitt's and non-Burkitt's
RT   type.";
RL   J. Immunol. 129:1336-1342(1982).
RX   PubMed=6811418; DOI=10.1016/S0171-2985(11)80031-8;
RA   Spira G., Koide N., Aman P., Ber R., Klein G.;
RT   "Truncated mu chain in a Burkitt lymphoma line (P3HR-1) and its fate
RT   in various hemapoietic somatic cell hybrids.";
RL   Immunobiology 162:199-209(1982).
RX   PubMed=7316467; DOI=10.1111/j.1469-1809.1980.tb00953.x;
RA   Povey S., Jeremiah S., Arthur E., Steel M., Klein G.;
RT   "Differences in genetic stability between human cell lines from
RT   patients with and without lymphoreticular malignancy.";
RL   Ann. Hum. Genet. 44:119-133(1980).
RX   PubMed=7849311; DOI=10.1182/blood.V85.4.893.bloodjournal854893;
RA   Stranks G., Height S.E., Mitchell P., Jadayel D.M., Yuille M.A.R.,
RA   De Lord C., Clutterbuck R.D., Treleaven J.G., Powles R.L.,
RA   Nacheva E., Oscier D.G., Karpas A., Lenoir G.M., Smith S.D.,
RA   Millar J.L., Catovsky D., Dyer M.J.S.;
RT   "Deletions and rearrangement of CDKN2 in lymphoid malignancy.";
RL   Blood 85:893-901(1995).
RX   PubMed=8344493; DOI=10.1096/fasebj.7.10.8344493;
RA   Bhatia K.G., Goldschmidts W., Gutierrez M.I., Gaidano G., Dalla-Favera R.,
RA   Magrath I.T.;
RT   "Hemi- or homozygosity: a requirement for some but not other p53
RT   mutant proteins to accumulate and exert a pathogenetic effect.";
RL   FASEB J. 7:951-956(1993).
RX   PubMed=8402660;
RA   O'Connor P.M., Jackman J., Jondle D., Bhatia K.G., Magrath I.T.,
RA   Kohn K.W.;
RT   "Role of the p53 tumor suppressor gene in cell cycle arrest and
RT   radiosensitivity of Burkitt's lymphoma cell lines.";
RL   Cancer Res. 53:4776-4780(1993).
RX   PubMed=8515068;
RA   Jain V.K., Judde J.-G., Max E.E., Magrath I.T.;
RT   "Variable IgH chain enhancer activity in Burkitt's lymphomas suggests
RT   an additional, direct mechanism of c-myc deregulation.";
RL   J. Immunol. 150:5418-5428(1993).
RX   PubMed=8558920;
RA   Dirks W.G., Zaborski M., Jager K., Challier C., Shiota M.,
RA   Quentmeier H., Drexler H.G.;
RT   "The (2;5)(p23;q35) translocation in cell lines derived from malignant
RT   lymphomas: absence of t(2;5) in Hodgkin-analogous cell lines.";
RL   Leukemia 10:142-149(1996).
RX   PubMed=9192833;
RA   Cherney B.W., Bhatia K.G., Sgadari C., Gutierrez M.I., Mostowski H.S.,
RA   Pike S.E., Gupta G., Magrath I.T., Tosato G.;
RT   "Role of the p53 tumor suppressor gene in the tumorigenicity of
RT   Burkitt's lymphoma cells.";
RL   Cancer Res. 57:2508-2515(1997).
RX   PubMed=9473234; DOI=10.1182/blood.V91.5.1680;
RA   Klangby U., Okan I., Magnusson K.P., Wendland M., Lind P., Wiman K.G.;
RT   "p16/INK4a and p15/INK4b gene methylation and absence of p16/INK4a
RT   mRNA and protein expression in Burkitt's lymphoma.";
RL   Blood 91:1680-1687(1998).
RX   PubMed=9973220;
RA   Gutierrez M.I., Cherney B.W., Hussain A., Mostowski H.S., Tosato G.,
RA   Magrath I.T., Bhatia K.G.;
RT   "Bax is frequently compromised in Burkitt's lymphomas with
RT   irreversible resistance to Fas-induced apoptosis.";
RL   Cancer Res. 59:696-703(1999).
RX   PubMed=10739008; DOI=10.1016/S0145-2126(99)00182-4;
RA   Inoue K., Kohno T., Takakura S., Hayashi Y., Mizoguchi H., Yokota J.;
RT   "Frequent microsatellite instability and BAX mutations in T cell acute
RT   lymphoblastic leukemia cell lines.";
RL   Leuk. Res. 24:255-262(2000).
RX   PubMed=11226526; DOI=10.1016/S0145-2126(00)00121-1;
RA   Inoue K., Kohno T., Takakura S., Hayashi Y., Mizoguchi H., Yokota J.;
RT   "Corrigendum to: Frequent microsatellite instability and BAX mutations
RT   in T cell acute lymphoblastic leukemia cell lines Leukemia Research 24
RT   (2000),255-262.";
RL   Leuk. Res. 25:275-278(2001).
RX   PubMed=12145705; DOI=10.1038/sj.leu.2402519;
RA   Langerak A.W., Moreau E., van Gastel-Mol E.J., van der Burg M.,
RA   van Dongen J.J.M.;
RT   "Detection of clonal EBV episomes in lymphoproliferations as a
RT   diagnostic tool.";
RL   Leukemia 16:1572-1573(2002).
RX   PubMed=16960149; DOI=10.1182/blood-2006-06-026500;
RA   Mestre-Escorihuela C., Rubio-Moscardo F., Richter J.A., Siebert R.,
RA   Climent J., Fresquet V., Beltran E., Agirre X., Marugan I., Marin M.,
RA   Rosenwald A., Sugimoto K.-J., Wheat L.M., Karran E.L., Garcia J.F.,
RA   Sanchez L., Prosper F., Staudt L.M., Pinkel D., Dyer M.J.S.,
RA   Martinez-Climent J.A.;
RT   "Homozygous deletions localize novel tumor suppressor genes in B-cell
RT   lymphomas.";
RL   Blood 109:271-280(2007).
RX   PubMed=18357372; DOI=10.3892/or.19.4.889;
RA   Pop I., Pop L., Vitetta E.S., Ghetie M.-A.;
RT   "Generation of multidrug resistant lymphoma cell lines stably
RT   expressing P-glycoprotein.";
RL   Oncol. Rep. 19:889-895(2008).
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
RX   PubMed=20454443; DOI=10.1155/2010/904767;
RA   Uphoff C.C., Denkmann S.A., Steube K.G., Drexler H.G.;
RT   "Detection of EBV, HBV, HCV, HIV-1, HTLV-I and -II, and SMRV in human
RT   and other primate cell lines.";
RL   J. Biomed. Biotechnol. 2010:904767.1-904767.23(2010).
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Burckstummer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17.1-17.13(2011).
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
RX   PubMed=22885699; DOI=10.1038/nature11378;
RA   Schmitz R., Young R.M., Ceribelli M., Jhavar S., Xiao W.-M., Zhang M.-L.,
RA   Wright G., Shaffer A.L. III, Hodson D.J., Buras E., Liu X.-L., Powell J.I.,
RA   Yang Y.-D., Xu W.-H., Zhao H., Kohlhammer H., Rosenwald A., Kluin P.,
RA   Muller-Hermelink H.-K., Ott G., Gascoyne R.D., Connors J.M.,
RA   Rimsza L.M., Campo E., Jaffe E.S., Delabie J., Smeland E.B.,
RA   Ogwang M.D., Reynolds S.J., Fisher R.I., Braziel R.M., Tubbs R.R.,
RA   Cook J.R., Weisenburger D.D., Chan W.C., Pittaluga S., Wilson W.,
RA   Waldmann T.A., Rowe M., Mbulaiteye S.M., Rickinson A.B., Staudt L.M.;
RT   "Burkitt lymphoma pathogenesis and therapeutic targets from structural
RT   and functional genomics.";
RL   Nature 490:116-120(2012).
RX   PubMed=24590883; DOI=10.1002/gcc.22161;
RA   Murga Penas E.-M., Schilling G., Behrmann P., Klokow M.,
RA   Vettorazzi E., Bokemeyer C., Dierlamm J.;
RT   "Comprehensive cytogenetic and molecular cytogenetic analysis of 44
RT   Burkitt lymphoma cell lines: secondary chromosomal changes
RT   characterization, karyotypic evolution, and comparison with primary
RT   samples.";
RL   Genes Chromosomes Cancer 53:497-515(2014).
RX   PubMed=25355872; DOI=10.1128/JVI.02570-14;
RA   Cao S.-B., Strong M.J., Wang X., Moss W.N., Concha M., Lin Z.,
RA   O'Grady T., Baddoo M., Fewell C., Renne R., Flemington E.K.;
RT   "High-throughput RNA sequencing-based virome analysis of 50 lymphoma
RT   cell lines from the Cancer Cell Line Encyclopedia project.";
RL   J. Virol. 89:713-729(2015).
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
RX   PubMed=25960936; DOI=10.4161/21624011.2014.954893;
RA   Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.;
RT   "A catalog of HLA type, HLA expression, and neo-epitope candidates in
RT   human cancer cell lines.";
RL   OncoImmunology 3:e954893.1-e954893.12(2014).
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
RX   PubMed=29892436; DOI=10.1098/rsos.172472;
RA   Shioda S., Kasai F., Watanabe K., Kawakami K., Ohtani A., Iemura M.,
RA   Ozawa M., Arakawa A., Hirayama N., Kawaguchi E., Tano T., Miyata S.,
RA   Satoh M., Shimizu N., Kohara A.;
RT   "Screening for 15 pathogenic viruses in human cell lines registered at
RT   the JCRB Cell Bank: characterization of in vitro human cells by viral
RT   infection.";
RL   R. Soc. Open Sci. 5:172472-172472(2018).
RX   PubMed=30285677; DOI=10.1186/s12885-018-4840-5;
RA   Tan K.-T., Ding L.-W., Sun Q.-Y., Lao Z.-T., Chien W., Ren X.,
RA   Xiao J.-F., Loh X.-Y., Xu L., Lill M., Mayakonda A., Lin D.-C., Yang H.,
RA   Koeffler H.P.;
RT   "Profiling the B/T cell receptor repertoire of lymphocyte derived cell
RT   lines.";
RL   BMC Cancer 18:940.1-940.13(2018).
RX   PubMed=30629668; DOI=10.1371/journal.pone.0210404;
RA   Uphoff C.C., Pommerenke C., Denkmann S.A., Drexler H.G.;
RT   "Screening human cell lines for viral infections applying RNA-Seq data
RT   analysis.";
RL   PLoS ONE 14:E0210404-E0210404(2019).
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).